Healthcare entity
Of the tracked stories, 2 of 4 also mention Wall Street Zen, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 3.9 for the same window. That works out to roughly 0.2 stories per week across a 147-day span.
Last mentioned: Sep 9, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 25 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 4 also mention Wall Street Zen, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 3.9 for the same window. That works out to roughly 0.2 stories per week across a 147-day span. Their average consequence score of 5.3 runs below the beat's 6.1 for that window. market-trends accounts for 2 of the 4 tracked stories, while 2 other categories carry the remainder. Bank of America appears in 4 tracked Healthcare stories published from March 12, 2026 through August 5, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 673 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Bank of America. Shared-story counts are live from our verified record — not editorial picks.
Teva Pharmaceutical's FY2026 EPS guidance fell short of the $2.17 consensus, while revenue projections of $16.5-$16.9B matched expectations. For healthcare leaders, the miss underscores ongoing generic drug pricing pressures and the importance of a diversified pipeline.
Wall Street Zen downgraded vaccine maker Novavax to sell, raising alarms in the healthcare sector. The stock traded at $7.41, far below its $13 consensus target, with a negative P/E of -12.78.
Intuitive Surgical's decision to extend force-feedback tool usage from 6 to 15 uses could accelerate robotic surgery adoption in hospitals, easing supply chain woes and lowering per-procedure costs without sacrificing revenue.
Source: The Motley Fool · James Halley (us)
Bank of America has raised its price target for Johnson & Johnson (JNJ), citing a strengthened outlook for the company's pharmaceutical and MedTech pipelines. The upgrade reflects growing investor confidence in JNJ's post-Kenvue strategy, which prioritizes high-margin innovation in oncology, immunology, and surgical robotics.
Source: finance.yahoo.com · insidermonkey.com
Bank of America is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
